PMID- 30619604
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220401
IS  - 0368-0762 (Print)
IS  - 2046-0481 (Electronic)
IS  - 0368-0762 (Linking)
VI  - 71
DP  - 2018
TI  - Comparative study to evaluate the voluntary acceptance of two liquid oral 
      formulations of ciclosporin in dogs.
PG  - 27
LID - 10.1186/s13620-018-0138-9 [doi]
LID - 27
AB  - BACKGROUND: The purpose of this study was to determine and compare the voluntary 
      acceptance of two oral liquid formulations of ciclosporin, investigational 
      Atopica(R) oral solution (Elanco Animal Health) and Cyclavance(R) Oral Solution 
      (Virbac), when given orally via syringe or offered freely after mixing with food 
      to dogs.Twenty-five adult mixed breed dogs were selected for this two-phase 
      study. In Phase 1, 12 (Group I) and 13 (Group II) dogs received Atopica(R) oral 
      solution and Cyclavance(R) Oral Solution, respectively, daily for 7 days via an 
      oral syringe. After a 3-day washout period, the dosing was switched for a further 
      7 days. For Phase 2, dosing was by acceptance from freely offered test article 
      mixed in a small amount of food, approximately 6 h after the routine morning 
      feeding. During the first part of this phase, normal daily ration of food offered 
      in the morning was continuously left in the cage. Group I was offered Atopica(R) 
      oral solution and Group II was offered Cyclavance(R) Oral Solution mixed with 
      ~ 25 g of food for 3 days. After another 2-day washout period, the test articles 
      were switched for another 3 days but the animals received food for only 1 h in 
      the morning. Five hours after the food was removed, the test articles with food 
      were offered in the same manner as in the first part of Phase 2. Animals were 
      also monitored for adverse events (AEs). RESULTS: During Phase I, voluntary 
      acceptance rates of 100 and 98.9% were noted for Atopica(R) oral solution and 
      Cyclavance(R) Oral Solution, respectively. The corresponding immediate prehension 
      rates during Phase 2 (Period 1) were 61.1 and 56.4%, respectively. During Phase 2 
      (Period 2), the immediate prehension rates were 69.2, 69.4 and 92.0% for Atopica(R) 
      oral solution, Cyclavance(R) Oral Solution and the positive control (DYNE(R); High 
      Calorie Liquid Dietary Supplement), respectively. Two adverse events of diarrhea 
      and vomiting, with a probable relationship to the test articles, were reported. 
      CONCLUSION: There was no significant difference in acceptance of the two oral 
      ciclosporin solutions, the investigational Atopica(R) oral solution (Elanco) and 
      Cyclavance(R) (Virbac) for dogs.
FAU - Kammanadiminti, Srinivas J
AU  - Kammanadiminti SJ
AUID- ORCID: 0000-0002-2997-2095
AD  - 1Elanco Animal Health, 2500 Innovation Way, Greenfield, IN 26140 USA. ISNI: 0000 
      0004 0638 9782. GRID: grid.414719.e
FAU - Carter, Lori A
AU  - Carter LA
AD  - Stillmeadow Inc., 12852 Park One Drive, Sugar Land, TX 77478 USA.
FAU - Seewald, Wolfgang
AU  - Seewald W
AD  - Elanco Animal Health, Mattenstrasse 24a, 4058 Basel, Switzerland.
FAU - Doucette, Kelly P
AU  - Doucette KP
AD  - 1Elanco Animal Health, 2500 Innovation Way, Greenfield, IN 26140 USA. ISNI: 0000 
      0004 0638 9782. GRID: grid.414719.e
LA  - eng
PT  - Journal Article
DEP - 20181229
PL  - Ireland
TA  - Ir Vet J
JT  - Irish veterinary journal
JID - 0100762
PMC - PMC6310966
OTO - NOTNLM
OT  - Acceptance
OT  - Atopic dermatitis
OT  - Ciclosporin
OT  - Consumption
OT  - Dog
OT  - Palatability
OT  - Prehension
COIS- Not applicableNot applicableSK, WS and KD are employees of Elanco Animal Health 
      and are therefore eligible for stock and stock options. LC is an employee of 
      Stillmeadow Inc.Springer Nature remains neutral with regard to jurisdictional 
      claims in published maps and institutional affiliations.
EDAT- 2019/01/09 06:00
MHDA- 2019/01/09 06:01
PMCR- 2018/12/29
CRDT- 2019/01/09 06:00
PHST- 2018/05/18 00:00 [received]
PHST- 2018/12/10 00:00 [accepted]
PHST- 2019/01/09 06:00 [entrez]
PHST- 2019/01/09 06:00 [pubmed]
PHST- 2019/01/09 06:01 [medline]
PHST- 2018/12/29 00:00 [pmc-release]
AID - 138 [pii]
AID - 10.1186/s13620-018-0138-9 [doi]
PST - epublish
SO  - Ir Vet J. 2018 Dec 29;71:27. doi: 10.1186/s13620-018-0138-9. eCollection 2018.